Pharmacodynamics<unk>  is a partial agonist and antagonist of serotonin, dopamine, and α-adrenergic receptors. Its specific binding and activation pattern on these receptors leads to a highly, if not completely, specific contraction of smooth uterus muscle via serotonin 5-HT2A receptors, while blood vessels are affected to a lesser extent compared to other ergot alkaloids. It has been found to interact with the serotonin 5-HT1A, 5-HT1B, 5-HT1E, 5-HT1F, 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT7 receptors.<unk>  is a synthetic analogue of ergometrine, a psychedelic alkaloid found in ergot, and many species of morning glory.<unk>  is a member of the ergoline family and chemically similar to LSD, ergine, ergometrine, and lysergic acid. According to Jonathan Ott,<unk>  produces LSD-like psychedelic effects at doses of 2 mg and above. This can be attributed to due to its agonistic action at the 5-HT2A–mGlu2 receptor protomers. Clinical efficacy occurs around 200 µg, ten times lower than the hallucinogenic threshold.<unk>  is an agonist of the serotonin 5-HT2B receptor and has been associated with cardiac valvulopathy. + Site Affinity (Ki nM) Efficacy (Emax %) Action 5-HT1A 1.5–2.0 ? Full agonist 5-HT1B 251 ? Full agonist 5-HT1D 0.86–2.9 70 Partial agonist 5-HT1E 89 ? Full agonist 5-HT1F 31 ? Full agonist 5-HT2A 0.35–1.1 ? Full agonist 5-HT2B 0.46–2.2 ? Full or partial agonist 5-HT2C 4.6–43.7 ? Full agonist 5-HT3 ? – – 5-HT5A ? ? Antagonist 5-HT6 ? ? Full agonist 5-HT7 11–52 ? Full agonist Notes: All sites are human except 5-HT1B (rat) and 5-HT7 (guinea pig).
Methylergometrine
Ergometrine
Indometacin
Indometacin farnesil
Xylometazoline
Drostanolone propionate
Alclometasone
Ethinylestradiol sulfonate